These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

623 related articles for article (PubMed ID: 30928465)

  • 1. Circulating bullous pemphigoid autoantibodies in the setting of negative direct immunofluorescence findings for bullous pemphigoid: A single-center retrospective review.
    Wang M; Lehman JS; Camilleri MJ; Drage LA; Wieland CN
    J Am Acad Dermatol; 2019 Aug; 81(2):472-479. PubMed ID: 30928465
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Usefulness of BP230 and BP180-NC16a enzyme-linked immunosorbent assays in the initial diagnosis of bullous pemphigoid: a retrospective study of 138 patients.
    Charneux J; Lorin J; Vitry F; Antonicelli F; Reguiai Z; Barbe C; Tabary T; Grange F; Bernard P
    Arch Dermatol; 2011 Mar; 147(3):286-91. PubMed ID: 21422334
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Positive Direct Immunofluorescence Is of Better Value than ELISA-BP180 and ELISA-BP230 Values for the Prediction of Relapse after Treatment Cessation in Bullous Pemphigoid: A Retrospective Study of 97 Patients.
    Ingen-Housz-Oro S; Plée J; Belmondo T; Maizières M; Pham BN; Hüe S; Ortonne N; Durlach A; Wolkenstein P; Chosidow O; Bernard P
    Dermatology; 2015; 231(1):50-5. PubMed ID: 25871736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation of autoantibodies against BP180/BP230 in response to topical corticosteroids in patients with bullous pemphigoid.
    Schneiderbauer R; Martinache S; Engstner M; Enk AH; Hadaschik EN
    Dermatol Ther; 2016 Nov; 29(6):419-423. PubMed ID: 27550573
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autoantibody Detection for Diagnosis in Direct Immunofluorescence-Negative Mucous Membrane Pemphigoid: Ocular and Other Sites Compared.
    Dart J; Setterfield J; Groves RW; Mee JB; Diercks GFH; Pas HH; Minassian D;
    Ophthalmology; 2021 Mar; 128(3):372-382. PubMed ID: 32745569
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BPDAI and ABSIS correlate with serum anti-BP180 NC16A IgG but not with anti-BP230 IgG in patients with bullous pemphigoid.
    Daneshpazhooh M; Ghiasi M; Lajevardi V; Nasiri N; Balighi K; Teimourpour A; Khosravi H; Saeidi V; Mahmoudi H; Chams-Davatchi C
    Arch Dermatol Res; 2018 Apr; 310(3):255-259. PubMed ID: 29423547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characteristics of IgG subclasses and complement deposition in BP230-type bullous pemphigoid.
    Zheng M; Ujiie H; Iwata H; Muramatsu K; Yoshimoto N; Ito T; Ujiie I; Shimizu S; Sato-Matsumura KC; Shimizu H
    J Eur Acad Dermatol Venereol; 2019 Mar; 33(3):595-600. PubMed ID: 30394605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative study of direct and indirect immunofluorescence and of bullous pemphigoid 180 and 230 enzyme-linked immunosorbent assays for diagnosis of bullous pemphigoid.
    Sárdy M; Kostaki D; Varga R; Peris K; Ruzicka T
    J Am Acad Dermatol; 2013 Nov; 69(5):748-753. PubMed ID: 23969034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and immunologic factors associated with bullous pemphigoid relapse during the first year of treatment: a multicenter, prospective study.
    Fichel F; Barbe C; Joly P; Bedane C; Vabres P; Truchetet F; Aubin F; Michel C; Jegou J; Grange F; Antonicelli F; Bernard P
    JAMA Dermatol; 2014 Jan; 150(1):25-33. PubMed ID: 24226428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biological predictors shared by dementia and bullous pemphigoid patients point out a cross-antigenicity between BP180/BP230 brain and skin isoforms.
    Julio TA; Vernal S; Massaro JD; Silva MC; Donadi EA; Moriguti JC; Roselino AM
    Immunol Res; 2018 Oct; 66(5):567-576. PubMed ID: 30220011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and Immunological Profiles of 14 Patients With Bullous Pemphigoid Without IgG Autoantibodies to the BP180 NC16A Domain.
    Nakama K; Koga H; Ishii N; Ohata C; Hashimoto T; Nakama T
    JAMA Dermatol; 2018 Mar; 154(3):347-350. PubMed ID: 29299596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and immunological profiles of anti-BP230-type bullous pemphigoid: Restriction of epitopes to the C-terminal domain of BP230, shown by novel ELISAs of BP230-domain specific recombinant proteins.
    Hayakawa T; Teye K; Hachiya T; Uehara R; Hashiguchi M; Kawakami T; Li X; Tsuchisaka A; Ohara K; Sogame R; Koga H; Hamada T; Ohata C; Furumura M; Ishii N; Fukano H; Shimozato K; Hashimoto T
    Eur J Dermatol; 2016 Apr; 26(2):155-63. PubMed ID: 27087683
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the combination of BP180-NC16a enzyme-linked immunosorbent assay and BP230 enzyme-linked immunosorbent assay in the diagnosis of bullous pemphigoid.
    Yang B; Wang C; Chen S; Chen X; Lu X; Tian H; Yu M; Zhang D; Shi Z; Zhou G; Zhang F
    Indian J Dermatol Venereol Leprol; 2012; 78(6):722-7. PubMed ID: 23075641
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of IgE autoantibodies to BP180 and BP230 and their relationship to clinical features in bullous pemphigoid.
    Hashimoto T; Ohzono A; Teye K; Numata S; Hiroyasu S; Tsuruta D; Hachiya T; Kuroda K; Hashiguchi M; Kawakami T; Ishii N
    Br J Dermatol; 2017 Jul; 177(1):141-151. PubMed ID: 27716903
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum levels of IgE anti-BP180 and anti-BP230 autoantibodies in patients with bullous pemphigoid.
    Ishiura N; Fujimoto M; Watanabe R; Nakashima H; Kuwano Y; Yazawa N; Echigo T; Okochi H; Tamaki K
    J Dermatol Sci; 2008 Feb; 49(2):153-61. PubMed ID: 17920818
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IgG autoantibody reactivity against bullous pemphigoid (BP) 180 and BP230 in elderly patients with pruritic dermatoses.
    Feliciani C; Caldarola G; Kneisel A; Podstawa E; Pfütze M; Pfützner W; Hertl M
    Br J Dermatol; 2009 Aug; 161(2):306-12. PubMed ID: 19485996
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-bullous pemphigoid 180 and 230 antibodies in a sample of unaffected subjects.
    Wieland CN; Comfere NI; Gibson LE; Weaver AL; Krause PK; Murray JA
    Arch Dermatol; 2010 Jan; 146(1):21-5. PubMed ID: 20083688
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bullous Pemphigoid and Neurologic Diseases: Toward a Specific Serologic Profile?
    Petrera MR; Tampoia M; Guida S; Abbracciavento L; Fumarulo R; Foti C
    Endocr Metab Immune Disord Drug Targets; 2018; 18(6):662-664. PubMed ID: 30062977
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elevated levels of circulating immunoglobulin E autoantibodies against BP180 and BP230 in an intractable case of bullous pemphigoid.
    Akasaka E; Hagiwara C; Takiyoshi N; Aizu T; Nakano H; Sawamura D; Ota T
    J Dermatol Sci; 2016 Oct; 84(1):110-113. PubMed ID: 27492811
    [No Abstract]   [Full Text] [Related]  

  • 20. Normal human skin is superior to monkey oesophagus substrate for detection of circulating BP180-NC16A-specific IgG antibodies in bullous pemphigoid.
    Emtenani S; Yuan H; Lin C; Pan M; Hundt JE; Schmidt E; Komorowski L; Stanley JR; Hammers CM
    Br J Dermatol; 2019 May; 180(5):1099-1106. PubMed ID: 30315657
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.